Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma - Scorecard - MDSpire

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

  • By

  • Chunxiao Ni

  • Jiaju Xu

  • Yu Pang

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Correction: Transforming an Immunologically “Cold” Tumor: Remarkable Response to Cadonilimab Combined with Chemotherapy in Microsatellite-Stable Pancreatic Cystadenocarcinoma

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care Setting

Key Highlights

  • Exceptional response observed with cadonilimab plus chemotherapy
  • Focus on immunologically 'cold' tumors
  • Correction acknowledges equal contribution of Jiaju Xu

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Cadonilimab combined with chemotherapy is discussed in the context of treatment.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

            • by Chunxiao Ni, Jiaju Xu, Yu Pang

            • June 10, 2026

            Related Content

            Heroes in motion – a six-year quality report and patient evaluation of a real-world exercise therapy program in pediatric oncology

            Case Report: Longitudinal analysis of local immunoregulatory mediators in a DLBCL vitreoretinal lymphoma receiving local chemotherapy

            Case Report: Fatal pneumonitis caused by Camrelizumab and Erlotinib in a patient with metastatic pancreatic cancer